| Followers | 391 |
| Posts | 18135 |
| Boards Moderated | 1 |
| Alias Born | 03/07/2014 |
Wednesday, September 09, 2020 11:04:06 AM
New AYTU/PINNACLE_COVID_TEST $999 For_25_Units - SHIPPING_BEGINS_TOMORROW !
$999 bucks for a 25 "test assay complete kit - all swabs, test slides, mixing reagents" to do 25 patients for $999.00 etc.
Begins SHIPPING SEPT 10, 2020 = TOMORROW !
I'm sure AYTU will be able to offer wholesale pricing to big customers such as hospitals and municipalities etc.
https://www.pblabs.com/products/pinnacle-rapid-antigen-test
Looks pretty damn impressive- THIS could be a BIG DEAL IMO.
"Pinnacle covID RAD Rapid Antigen Test
$ 999.99
At a glance: The Pinnacle covID RAD rapid antigen test contains 25 test cassettes, buffer solution, swabs, extraction tubes and dropper tips, package insert and quick reference guide for sample collection and results interpretation. The test is performed using a nasal (nasopharyngeal) swab with no additional equipment. For Professional Use Only. For In Vitro Diagnostic Use Only. Ships September 10, 2020. For questions or ordering information, call 1-877-465-0826.
"
AND
"The rapid SARS CoV-2 Antigen test
The Pinnacle Cov-ID RAD Rapid Antigen Detection Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2 in nasopharyngeal specimen (NP) from individuals who are suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests, or by similarly qualified non-U.S. laboratories and as applicable, Point of Care (POC) testing.
"
AND
"The Pinnacle covID RAD Rapid Antigen Detection test uses a disposable swab (included) to aid in the detection of novel Coronavirus with 85%¹ sensitivity and ~99%² specificity in 15 minutes or less. Rapid antigen testing has been thought of as the missing link in the fight against Coronavirus, because antibody tests detect active and prior infections. In asymptotic individuals, they may have contracted SARS-CoV2 up to 90 days prior to diagnosis, and are effectively "cured". With an antigen test, providers can be sure positive results are indicative of a current infection, because once the infection is gone, the antigen disappears."
It's real and AYTU is a distributor now- "EXCLUSIVE" distributor, we don't know ????
The Pinnacle "home colon cancer" screening test is the biggest selling in America and a big EU market too - so they know what the hell they're doing it seems to me:
https://www.pblabs.com/pages/partners
I'd not be surprised to see AYTU make an offer to buy-out private owned Pinnacle - the product lines are PERFECTLY aligned with the AYTU biz model.
Wonder if Josh is going to make a go at buying them and getting the "home colon cancer test" and all the rest ???
$999 bucks for a 25 "test assay complete kit - all swabs, test slides, mixing reagents" to do 25 patients for $999.00 etc.
Begins SHIPPING SEPT 10, 2020 = TOMORROW !
I'm sure AYTU will be able to offer wholesale pricing to big customers such as hospitals and municipalities etc.
https://www.pblabs.com/products/pinnacle-rapid-antigen-test
Looks pretty damn impressive- THIS could be a BIG DEAL IMO.
"Pinnacle covID RAD Rapid Antigen Test
$ 999.99
At a glance: The Pinnacle covID RAD rapid antigen test contains 25 test cassettes, buffer solution, swabs, extraction tubes and dropper tips, package insert and quick reference guide for sample collection and results interpretation. The test is performed using a nasal (nasopharyngeal) swab with no additional equipment. For Professional Use Only. For In Vitro Diagnostic Use Only. Ships September 10, 2020. For questions or ordering information, call 1-877-465-0826.
"
AND
"The rapid SARS CoV-2 Antigen test
The Pinnacle Cov-ID RAD Rapid Antigen Detection Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2 in nasopharyngeal specimen (NP) from individuals who are suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate and high complexity tests, or by similarly qualified non-U.S. laboratories and as applicable, Point of Care (POC) testing.
"
AND
"The Pinnacle covID RAD Rapid Antigen Detection test uses a disposable swab (included) to aid in the detection of novel Coronavirus with 85%¹ sensitivity and ~99%² specificity in 15 minutes or less. Rapid antigen testing has been thought of as the missing link in the fight against Coronavirus, because antibody tests detect active and prior infections. In asymptotic individuals, they may have contracted SARS-CoV2 up to 90 days prior to diagnosis, and are effectively "cured". With an antigen test, providers can be sure positive results are indicative of a current infection, because once the infection is gone, the antigen disappears."
It's real and AYTU is a distributor now- "EXCLUSIVE" distributor, we don't know ????
The Pinnacle "home colon cancer" screening test is the biggest selling in America and a big EU market too - so they know what the hell they're doing it seems to me:
https://www.pblabs.com/pages/partners
I'd not be surprised to see AYTU make an offer to buy-out private owned Pinnacle - the product lines are PERFECTLY aligned with the AYTU biz model.
Wonder if Josh is going to make a go at buying them and getting the "home colon cancer test" and all the rest ???
Posts contain only my amateur opinions, personal views and thoughts. I discuss stocks as a hobby only. Always do one's own due diligence before investing.
Recent AYTU News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:08:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:05:56 PM
- Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results • ACCESS Newswire • 05/13/2026 08:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 • ACCESS Newswire • 05/06/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:08:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/03/2026 09:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:05:35 PM
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results • ACCESS Newswire • 02/03/2026 09:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 • ACCESS Newswire • 01/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:29 PM
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026 • ACCESS Newswire • 01/20/2026 09:05:00 PM
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA • ACCESS Newswire • 01/20/2026 02:00:00 PM
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 • ACCESS Newswire • 01/13/2026 09:15:00 PM
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City • ACCESS Newswire • 01/12/2026 01:00:00 PM
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City • ACCESS Newswire • 12/18/2025 02:00:00 PM
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults • ACCESS Newswire • 12/15/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:05:23 PM
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference • ACCESS Newswire • 11/24/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:26:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:08:28 PM
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results • ACCESS Newswire • 11/13/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:35:20 PM
- Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 • ACCESS Newswire • 11/05/2025 09:05:00 PM
- Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) • ACCESS Newswire • 10/28/2025 01:00:00 PM
